John A Kaufman1, Claire Mattison2, Amanda M Fretts3, Jason G Umans4, Shelley A Cole5, V Saroja Voruganti6, Walter Goessler7, Lyle G Best8, Ying Zhang9, Maria Tellez-Plaza10, Ana Navas-Acien11, Matthew O Gribble12. 1. Department of Epidemiology, Emory University, Atlanta, GA, USA. Electronic address: jakauf2@emory.edu. 2. Department of Environmental Health, Emory University, Atlanta, GA, USA. 3. Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, USA. 4. Department of Medicine, Georgetown University Medical Center, Washington, DC, USA. 5. Texas Biomedical Research Institute, San Antonio, TX, USA. 6. Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA. 7. Institute of Chemistry, University of Graz, Graz, Austria. 8. Missouri Breaks Industries Research, Inc., Eagle Butte, SD, United States. 9. Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 10. Department of Chronic Diseases Epidemiology, National Center for Epidemiology, Carlos III Health Institute, Madrid, Spain. 11. Department of Environmental Health Sciences, Columbia University, New York, NY, USA. 12. Department of Epidemiology, Emory University, Atlanta, GA, USA; Department of Environmental Health, Emory University, Atlanta, GA, USA.
Abstract
BACKGROUND: Arsenic has been associated with hypertension, though it is unclear whether associations persist at the exposure concentrations (e.g. <100 μg/L) in drinking water occurring in parts of the Western United States. METHODS: We assessed associations between arsenic biomarkers and systolic blood pressure (SBP), diastolic blood pressure (DBP), and hypertension in the Strong Heart Family Study, a family-based cohort of American Indians from the Northern plains, Southern plains, and Southwest. We included 1910 participants from three study centers with complete baseline visit data (2001-2003) in the cross-sectional analysis of all three outcomes, and 1453 participants in the prospective analysis of incident hypertension (follow-up 2006-2009). We used generalized estimating equations with exchangeable correlation structure conditional on family membership to estimate the association of arsenic exposure biomarker levels with SBP or DBP (linear regressions) or hypertension prevalence and incidence (Poisson regressions), adjusting for urine creatinine, urine arsenobetaine, and measured confounders. RESULTS: We observed cross-sectional associations for a two-fold increase in inorganic and methylated urine arsenic species of 0.64 (95% CI: 0.07, 1.35) mm Hg for SBP, 0.49 (95% CI: 0.03, 1.02) mm Hg for DBP, and a prevalence ratio of 1.10 (95% CI: 1.01, 1.21) for hypertension in fully adjusted models. During follow-up, 14% of subjects developed hypertension. We observed non-monotonic relationships between quartiles of arsenic and incident hypertension. Effect estimates were null for incident hypertension with continuous exposure metrics. Stratification by study site revealed elevated associations in Arizona, the site with the highest arsenic levels, while results for Oklahoma and North and South Dakota were largely null. Blood pressure changes with increasing arsenic concentrations were larger for those with diabetes at baseline. CONCLUSIONS: Our results suggest a modest cross-sectional association of arsenic exposure biomarkers with blood pressure, and possible non-linear effects on incident hypertension.
BACKGROUND: Arsenic has been associated with hypertension, though it is unclear whether associations persist at the exposure concentrations (e.g. <100 μg/L) in drinking water occurring in parts of the Western United States. METHODS: We assessed associations between arsenic biomarkers and systolic blood pressure (SBP), diastolic blood pressure (DBP), and hypertension in the Strong Heart Family Study, a family-based cohort of American Indians from the Northern plains, Southern plains, and Southwest. We included 1910 participants from three study centers with complete baseline visit data (2001-2003) in the cross-sectional analysis of all three outcomes, and 1453 participants in the prospective analysis of incident hypertension (follow-up 2006-2009). We used generalized estimating equations with exchangeable correlation structure conditional on family membership to estimate the association of arsenic exposure biomarker levels with SBP or DBP (linear regressions) or hypertension prevalence and incidence (Poisson regressions), adjusting for urine creatinine, urine arsenobetaine, and measured confounders. RESULTS: We observed cross-sectional associations for a two-fold increase in inorganic and methylated urine arsenic species of 0.64 (95% CI: 0.07, 1.35) mm Hg for SBP, 0.49 (95% CI: 0.03, 1.02) mm Hg for DBP, and a prevalence ratio of 1.10 (95% CI: 1.01, 1.21) for hypertension in fully adjusted models. During follow-up, 14% of subjects developed hypertension. We observed non-monotonic relationships between quartiles of arsenic and incident hypertension. Effect estimates were null for incident hypertension with continuous exposure metrics. Stratification by study site revealed elevated associations in Arizona, the site with the highest arsenic levels, while results for Oklahoma and North and South Dakota were largely null. Blood pressure changes with increasing arsenic concentrations were larger for those with diabetes at baseline. CONCLUSIONS: Our results suggest a modest cross-sectional association of arsenic exposure biomarkers with blood pressure, and possible non-linear effects on incident hypertension.
Authors: T Casale; M V Rosati; A Capozzella; F Sinibaldi; A Suppi; C Sacco; M Marrocco; B Scala; R Giubilati; V Di Giorgio; F Tomei; G Tomei; A Sancini Journal: Clin Ter Date: 2015
Authors: Miranda R Jones; Maria Tellez-Plaza; A Richey Sharrett; Eliseo Guallar; Ana Navas-Acien Journal: Epidemiology Date: 2011-03 Impact factor: 4.822
Authors: M K O'Rourke; P K Van de Water; S Jin; S P Rogan; A D Weiss; S M Gordon; D M Moschandreas; M D Lebowitz Journal: J Expo Anal Environ Epidemiol Date: 1999 Sep-Oct
Authors: Gernot Pichler; Maria Grau-Perez; Maria Tellez-Plaza; Jason Umans; Lyle Best; Shelley Cole; Walter Goessler; Kevin Francesconi; Jonathan Newman; Josep Redon; Richard Devereux; Ana Navas-Acien Journal: Circ Cardiovasc Imaging Date: 2019-05 Impact factor: 7.792
Authors: Miranda J Spratlen; Maria Grau-Perez; Lyle G Best; Joseph Yracheta; Mariana Lazo; Dhananjay Vaidya; Poojitha Balakrishnan; Mary V Gamble; Kevin A Francesconi; Walter Goessler; Shelley A Cole; Jason G Umans; Barbara V Howard; Ana Navas-Acien Journal: Am J Epidemiol Date: 2018-08-01 Impact factor: 4.897
Authors: Margaret Kurzius-Spencer; Jefferey L Burgess; Robin B Harris; Vern Hartz; Jason Roberge; Shuang Huang; Chiu-Hsieh Hsu; M K O'Rourke Journal: J Expo Sci Environ Epidemiol Date: 2013-07-17 Impact factor: 5.563
Authors: Irina Mordukhovich; Robert O Wright; Howard Hu; Chitra Amarasiriwardena; Andrea Baccarelli; Augusto Litonjua; David Sparrow; Pantel Vokonas; Joel Schwartz Journal: Environ Health Perspect Date: 2011-08-30 Impact factor: 9.031